Amgen Q3 revenue $6.9B (+4% YoY); GAAP EPS $3.22 (-19%); Non-GAAP EPS $4.96 (+6%)

AMGEN INC

2023-Q3 EPS reported $11.06 revenue$19,994,000,000

Total revenues $6.9B (+4% YoY); product sales +5% on 11% volume growth.
GAAP EPS $3.22 (down 19% YoY), includes ~$650M impairment for discontinued AMG 340.
Non-GAAP EPS $4.96 (+6% YoY); non-GAAP operating margin 52.0%.
Free cash flow $2.5B in Q3 vs $2.8B in prior year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AMGEN INC reported third quarter of 2023 results: revenue $6.9 billion.

Period: third quarter of 2023
Revenue: $6.9 billion
Result: reported results

Exact text from the filing

of the Horizon acquisition, Amgen has added rare disease medicines that fit well with our broad innovative portfolio." Key results include: • Total revenues increased 4% to $6.9 billion in comparison to the third quarter of 2022, resulting from a 5% increase in product sales. Produ ct sales growth was driven by 11% volume growth, partially offset by 3% lower net

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

AMGEN INC filing history →

Source: SEC EDGAR

accession 0000318154-23-000061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.